Summary
Using a pharmacokinetic/pharmacodynamic (PK/PD) target algorithm, the in vitro potency of CXA-201 (CXA101/tazobactam), a novel cephalosporin and b-lactamase inhibitor combination that is being developed to treat serious bacterial infections, was reported to be lower in isolates from the intensive care unit (ICU) compared with non-ICU isolates.
- Infectious Disease Clinical Trials
- Bacterial Infections
- © 2011 MD Conference Express
Tools
CXA-201 Effective against Common ICU Pathogens, Including MDR Gram-Negative Pathogens and Pseudomonas aeruginosa
Permalink:
Table of contents
Cited By...
- No citing articles found.